A practical review on carfilzomib in multiple myeloma

European Journal of Haematology
Eli MuchtarHila Magen

Abstract

Carfilzomib, a second-generation proteasome inhibitor, has been increasingly used in relapsed/refractory multiple myeloma (MM) since its approval by the American food and drug administration (FDA) in the summer of 2012. The drug is active as a single agent and in combination with other antimyeloma agents. As a result of its efficacy and safety in the relapsed/refractory setting, carfilzomib is being evaluated in patients with newly diagnosed MM as well as in high-risk smoldering MM. This review will give a comprehensive summary of the drug, including its mechanism of action, the evaluated doses and schedules as well as a summary of the main clinical trials in the relapsed/refractory and newly diagnosed settings. A focus will be placed upon certain subgroups of interest as well as a description of the toxicity associated with carfilzomib use and a clinical perspective on toxicity management.

References

Jun 15, 2007·British Journal of Haematology·Orciuolo EnricoPetrini Mario
Jul 10, 2007·Cancer Research·Susan D DemoMark K Bennett
Sep 16, 2010·Biochimica Et Biophysica Acta·Yi-Fan Li, Xuejun Wang
Oct 12, 2010·The Lancet Oncology·Michel DelforgePieter Sonneveld
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosJésus San Miguel
Jul 5, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Melissa AlsinaAndre Goy
Nov 3, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Zhengping WangJeffrey R Infante
Mar 29, 2013·Molecular Cancer Therapeutics·Holly A F StessmanBrian G Van Ness
Aug 27, 2013·Cancer Chemotherapy and Pharmacology·Kyriakos P PapadopoulosJeffery R Infante
Apr 22, 2014·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Rimda WanchooKenar D Jhaveri
May 7, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xuemei CaiJoshua P Klein
Sep 17, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kyriakos P PapadopoulosAshraf Badros
Nov 22, 2014·Journal of Clinical Apheresis·Matthew R SullivanNancy M Dunbar
Dec 9, 2014·The New England Journal of Medicine·A Keith StewartUNKNOWN ASPIRE Investigators
Feb 13, 2015·Future Oncology·Lindsay C StansfieldFrancis K Buadi
Apr 30, 2015·The New England Journal of Medicine·A Keith Stewart, Antonio Palumbo
Apr 30, 2015·The New England Journal of Medicine·Dennis L Cooper
Jun 6, 2015·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Abdel Rahman Lataifeh, Ahmad Nusair
Sep 29, 2015·Clinical Kidney Journal·Ahad LodhiManish Suneja
Jan 16, 2016·Blood Cancer Journal·A RosenthalA K Stewart

❮ Previous
Next ❯

Citations

Jul 19, 2016·Expert Review of Hematology·Despoina FotiouEfstathios Kastritis
Aug 12, 2016·Future Oncology·Wilson I GonsalvesFrancis K Buadi
Jun 28, 2016·Journal of the American Chemical Society·Tanja SchirmeisterBernd Engels
Oct 21, 2016·Expert Opinion on Pharmacotherapy·Maria GavriatopoulouMeletios A Dimopoulos
Oct 25, 2016·International Journal of Molecular Sciences·Philip EganH Denis Alexander
Jan 25, 2017·Expert Review of Hematology·Annamaria BrioliMarie Von Lilienfeld-Toal
Nov 15, 2017·Expert Opinion on Pharmacotherapy·Dimitrios C ZiogasMeletios A Dimopoulos
Jul 31, 2018·Future Oncology·Susanne Strifler, Stefan Knop
May 24, 2018·Cardiovascular & Hematological Disorders Drug Targets·Ota Fuchs
Jun 18, 2019·Clinical Transplantation·Kevin S Shah, Jignesh Patel
Jul 13, 2019·International Journal of Molecular Sciences·Nicolas AlbornozPatricia Burgos
Apr 18, 2020·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sikander AilawadhiRobert Z Orlowski
Sep 23, 2020·Panminerva Medica·Vittorio MontefuscoClaudio Cerchione
Mar 23, 2021·British Journal of Haematology·Jonathan SiveUNKNOWN British Society of Haematology
Feb 5, 2022·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·David Garrido, Eloísa Riva

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.